ROR1 Gene: Receptor Tyrosine Kinase-Like Orphan Receptor 1
A key oncofetal surface antigen involved in Wnt signaling, cancer progression, and potential targeted therapy.
Gene Information Card
| Symbol | ROR1 |
|---|---|
| Full Name | Receptor Tyrosine Kinase-Like Orphan Receptor 1 |
| Gene Type | Protein coding |
| Chromosomal Location | 1p31.3 |
| NCBI Gene ID | 4919 ncbi.nlm.nih.gov/gene/4919 |
| Ensembl ID | ENSG00000185483 |
| UniProt ID | Q01973 |
| OMIM ID | 602336 |
| HGNC ID | 10256 |
| Aliases | NTRKR1, dJ537F10.1 |
Description
ROR1 (Receptor Tyrosine Kinase-Like Orphan Receptor 1) is a type I transmembrane protein belonging to the ROR family of receptor tyrosine kinases. It acts as a receptor for Wnt ligands, particularly Wnt5a, and plays a critical role in embryonic development, including skeletal, cardiac, and neural morphogenesis. In adults, ROR1 expression is largely silenced, but it is re-expressed in various malignancies, where it promotes tumor cell survival, proliferation, migration, and epithelial-mesenchymal transition. Its restricted normal expression and high tumor expression make it an attractive target for cancer therapy.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Chronic lymphocytic leukemia (CLL) | ROR1 is overexpressed on CLL cells and mediates Wnt5a-induced signaling that promotes cell survival and proliferation. | High expression in CLL; associated with poor prognosis (PMID: 21868554). |
| Breast cancer | ROR1 expression correlates with aggressive triple-negative subtype and promotes tumor invasion and metastasis via non-canonical Wnt signaling. | Overexpressed in breast cancer tissues; knockdown reduces tumor growth in xenografts (PMID: 27098601). |
| Lung cancer | ROR1 contributes to tumor growth and resistance to apoptosis; its expression is associated with poor survival. | Detected in non-small cell lung cancer; inhibition reduces tumor progression (PMID: 27507842). |
| Ovarian cancer | ROR1 supports tumor cell migration and invasion, and its high expression correlates with advanced stage. | Overexpressed in ovarian cancer cell lines and tissues (PMID: 27381629). |
| Pancreatic cancer | ROR1 promotes epithelial-mesenchymal transition and chemoresistance. | Expression elevated in pancreatic cancer; silencing sensitizes cells to gemcitabine (PMID: 28202524). |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Adipose tissue | 0.0 | Not detected |
| Brain | 0.0 | Not detected |
| Breast | 0.0 | Not detected |
| Colon | 0.0 | Not detected |
| Kidney | 0.0 | Not detected |
| Liver | 0.0 | Not detected |
| Lung | 0.0 | Not detected |
| Ovary | 0.0 | Not detected |
| Pancreas | 0.0 | Not detected |
| Skin | 0.0 | Not detected |
| Spleen | 0.0 | Not detected |
| Testis | 0.0 | Not detected |
| Thymus | 0.0 | Not detected |
| Uterus | 0.0 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| CLL cells (primary) | Not applicable | High surface expression (flow cytometry) |
| MCF7 (breast cancer) | 0.0 | Low expression |
| MDA-MB-231 (breast cancer) | 0.0 | High expression (triple-negative) |
| A549 (lung cancer) | 0.0 | Moderate expression |
| OVCAR3 (ovarian cancer) | 0.0 | High expression |
| PANC-1 (pancreatic cancer) | 0.0 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1660A>G (p.Ile554Val) | Missense | Rare (0.01% in gnomAD) | Unknown; not reported in ClinVar |
| c.1960C>T (p.Arg654Cys) | Missense | Rare (0.005% in gnomAD) | Unknown; not reported in ClinVar |
| c.2201G>A (p.Arg734His) | Missense | Rare (0.003% in gnomAD) | Unknown; not reported in ClinVar |
Mutation functional classification
Loss of Function (LOF)
No loss-of-function mutations have been characterized in ROR1. Germline loss is likely lethal due to developmental defects.
Gain of Function (GOF)
Somatic mutations in ROR1 are rare and not clearly activating. Overexpression, not mutation, is the primary oncogenic mechanism.
Dominant Negative (DN)
No dominant-negative mutations have been reported for ROR1.
View complete mutation data：
Gene Ontology (GO)
| • GO:0004672 (protein kinase activity) | • GO:0004714 (transmembrane receptor protein tyrosine kinase activity) |
| • GO:0004888 (transmembrane signaling receptor activity) | • GO:0005515 (protein binding) |
| • GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway) | • GO:0016301 (kinase activity) |
| • GO:0016310 (phosphorylation) | • GO:0030182 (neuron differentiation) |
| • GO:0048013 (ephrin receptor signaling pathway) | • GO:0060070 (canonical Wnt signaling pathway) |
Pathways
• Wnt signaling pathway (non-canonical
• planar cell polarity)
• PI3K/AKT signaling pathway
• MAPK/ERK signaling pathway
• NF-kB signaling pathway
Protein Summary
ROR1 is a 937-amino acid type I transmembrane protein with an extracellular region containing immunoglobulin-like, cysteine-rich (Frizzled-like), and Kringle domains, and an intracellular region with a tyrosine kinase domain and two serine/threonine-rich domains. It functions as a receptor for Wnt5a, activating non-canonical Wnt signaling pathways that regulate cell polarity, migration, and survival. In cancer, ROR1 is aberrantly expressed and promotes tumor progression. Its structure and surface accessibility make it a promising target for monoclonal antibody and CAR-T therapies.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ROR1 Knockout HEK293 Cell Line | EDJ-KQ327 | Human | 4919 | Details Get a Quote |
| ROR1 Knockout HeLa Cell Line | EDJ-KQ18303 | Human | 4919 | Details Get a Quote |
| ROR1 Knockout A-549 Cell Line | EDJ-KQ18491 | Human | 4919 | Details Get a Quote |
| ROR1 Knockout HCT 116 Cell Line | EDJ-KQ18492 | Human | 4919 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
